MYMD insider filings
MyMD Pharmaceuticals, Inc. — 31 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-08-24. Screen MYMD transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MYMD between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — MyMD Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-08-24 | 4 | Rivard Paul — Chief Legal Officer | Purchase (P): 150,000 @ $1.11 | EDGAR |
| 2023-08-18 | 4 | Rivard Paul — Chief Legal Officer | Purchase (P): 25,000 @ $1.12 | EDGAR |
| 2023-06-09 | 4 | Rivard Paul — Chief Legal Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Uzonwanne Jude — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Silverman Joshua — Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | EAGLE CRAIG — Director | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Schreiber Christopher C — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Chapman Christopher C JR — President, Chief Med. Officer, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | White Billy Joe — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Kaplin Adam — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-04-05 | 4 | Chapman Christopher C JR — President, Chief Med. Officer, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2022-12-08 | 4 | Rivard Paul — EVP of Operations, GC | Purchase (P): 10,000 @ $1.53 | EDGAR |
| 2021-11-29 | 4 | Silverman Joshua — Director | Purchase (P): 6,734 @ $6.30 · Purchase (P): 3,266 @ $7.09 · Purchase (P): 5,000 @ $7.55 | EDGAR |
| 2021-11-24 | 4 | Rivard Paul — EVP of Operations, GC | Purchase (P): 15,000 @ $6.03 | EDGAR |
| 2021-10-15 | 4 | Uzonwanne Jude — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Kaplin Adam — Chief Scientific Officer | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Schreiber Christopher C — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | White Billy Joe — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | EAGLE CRAIG — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Silverman Joshua — Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Chapman Christopher C JR — President, Chief Med. Officer, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Rivard Paul — EVP of Operations, GC | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2021-04-22 | 4 | EAGLE CRAIG — Director | Grant/award (A): 482,375 (derivative) | EDGAR |
| 2021-04-21 | 4 | Uzonwanne Jude — Director | Grant/award (A): 115,770 (derivative) | EDGAR |
| 2021-04-21 | 4 | Kaplin Adam — Chief Scientific Officer | Grant/award (A): 154,360 (derivative) | EDGAR |
| 2021-04-21 | 4 | Schreiber Christopher C — Director | Option exercise (M): 131,750 · Tax withholding (F): 46,113 @ $4.94 · Option exercise (M): 131,750 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Chapman Christopher C JR — President, Chief Med. Officer, Director | Grant/award (A): 96,475 · Grant/award (A): 38,590 (derivative) · Grant/award (A): 77,180 (derivative) · Grant/award (A): 77,180 (derivative) · Grant/award (A): 96,475 (derivative) | EDGAR |
| 2021-04-20 | 4 | Rivard Paul — EVP of Operations, GC | Grant/award (A): 77,180 (derivative) · Grant/award (A): 77,180 (derivative) | EDGAR |
| 2021-04-20 | 4 | Silverman Joshua — Director | Option exercise (M): 109,500 · Tax withholding (F): 38,325 @ $4.94 · Option exercise (M): 109,500 (derivative) @ $0 | EDGAR |
| 2021-04-20 | 4 | White Billy Joe — Director | Option exercise (M): 109,500 · Tax withholding (F): 38,325 @ $4.94 · Option exercise (M): 109,500 (derivative) @ $0 | EDGAR |
| 2021-04-20 | 4 | SCHROEDER ROBERT C — Director | Option exercise (M): 43,930 · Tax withholding (F): 14,694 @ $4.94 · Option exercise (M): 43,930 (derivative) @ $0 | EDGAR |
Recent 8-K events — MyMD Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.02 — Termination of a Material Definitive Agreement 8.01 — Other Events | EDGAR |
| 2026-03-13 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MYMD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs